Who are treatment with dorzolamide/timolol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): tafluprost and dorzolamide/timolol, Drug: dorzolamide/timolol.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/treatment-with-dorzolamide-timolol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

treatment with dorzolamide/timolol — Competitive Intelligence Brief

treatment with dorzolamide/timolol (treatment with dorzolamide/timolol) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Carbonic anhydrase inhibitor / Beta-blocker combination. Area: Ophthalmology.

marketed Carbonic anhydrase inhibitor / Beta-blocker combination Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2) Ophthalmology Small molecule Live · refreshed every 30 min

Target snapshot

treatment with dorzolamide/timolol (treatment with dorzolamide/timolol) — Aristotle University Of Thessaloniki. Dorzolamide/timolol is a fixed-dose combination that reduces intraocular pressure by inhibiting carbonic anhydrase (dorzolamide) and blocking beta-adrenergic receptors (timolol).

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
treatment with dorzolamide/timolol TARGET	treatment with dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Carbonic anhydrase inhibitor / Beta-blocker combination	Carbonic anhydrase II; Beta-adrenergic receptors (β1 and β2)
tafluprost and dorzolamide/timolol	tafluprost and dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Prostaglandin analogue / carbonic anhydrase inhibitor / beta-blocker combination	Prostaglandin F receptor (FP receptor), carbonic anhydrase II, beta-1 and beta-2 adrenergic receptors
Drug: dorzolamide/timolol	Drug: dorzolamide/timolol	Aristotle University Of Thessaloniki	marketed	Carbonic anhydrase inhibitor / Beta-blocker combination	Carbonic anhydrase II / Beta-adrenergic receptors (β1 and β2)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Carbonic anhydrase inhibitor / Beta-blocker combination class)

Aristotle University Of Thessaloniki · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). treatment with dorzolamide/timolol — Competitive Intelligence Brief. https://druglandscape.com/ci/treatment-with-dorzolamide-timolol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab